BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Telaprevir: Interim Phase II data

Interim data from 59 treatment-naïve patients with chronic HCV genotype 1 infection in the ongoing, open-label, U.S. and New Zealand Phase II ZENITH trial showed that twice-daily 100 and 400 mg VX-222 plus 1,125 mg telaprevir, Pegasys peginterferon alfa-2a and Copegus ribavirin led to undetectable HCV RNA levels at week 2 in 38% (n=29) and 57% (n=30) of patients, respectively. Additionally, the low- and high-dose combination regimens produced undetectable HCV RNA levels at both weeks 2 and 8 in 38% and 50% of patients, respectively. Patients with undetectable virus at weeks...

Read the full 463 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >